Skip to content

Vir Biotechnology, Inc. VIR Preferred Stock, Shares Issued

Preferred Stock, Shares Issued at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
Biohaven logo
BiohavenBHVN
Moderna logo
ModernaMRNA
Revvity logo
RevvityRVTY

Other financials

Income statement

See full
Revenue-$29.0K-101%
Gross profit$1.2M-60.2%
Operating income-$132.3M+5.2%
Net income-$125.7M-3.9%
EPS (diluted)-$0.85+3.4%

Balance sheet

See full
Cash & equivalents$283.0M-23.1%
Total debt$95.6M-0.5%
Total equity$812.8M-22.1%
Total assets$1.0B-21.6%

Cash flow

See full
Operating cash flow-$132.4M-69.5%
CapEx$390.0K-76.1%
Free cash flow-$132.8M-66.5%

Valuation

See full
Market cap$1.68B+61.1%

Profitability

See full
Gross margin96.1%-2.7pp
Operating margin-720.8%-313pp
Net margin-676%-291pp
FCF margin-686.5%-273pp

Returns & leverage

See full
Return on equity-47.7%+3.6pp
Debt / equity0.1×0.0×
Current ratio7.1×+0.3×

Where this comes from

Reported directly by Vir Biotechnology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesIssued.

The official record: Vir Biotechnology, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Vir Biotechnology, Inc.'s preferred stock, shares issued?
Vir Biotechnology, Inc. (VIR) reported preferred stock, shares issued of $0 in Q1 2026.